The Power of Our Business

Investor Relations

InterCure Ltd. (Tel-Aviv Stock Exchange: INCR), is disrupting the $42 billion hypertension industry with the world’s 1st FDA-cleared, OTC blood pressure treatment device, RESPeRATE®. In a market where 7 out of 10 hypertension patients suffer from inadequately-controlled blood pressure despite the availability of more than 100 blood pressure medications, RESPeRATE offers an effective non-drug therapy that is clinically proven, with excellent compliance and no side effects. RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. 10 separate clinical studies have proven the device’s efficacy and safety and RESPeRATE is now featured in over 20 popular and professional text books including Mayo Clinic’s On High Blood Pressure and the American Heart Association’s Hypertension Primer.

With over 100,000 units sold, thousands of supportive clinicians worldwide and one of the world’s most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.

InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia, and multiple other medical conditions.

For further information please contact Arik Kleinstein, investors@InterCure.com

Intercure's Highlights

• Large Markets with Unmet Needs
  InterCure’s products target some of the most widespread and costly chronic diseases such as hypertension, insomnia and heart failure.
  
  
• Significant Medical Breakthrough
  The broadly-patented Device-Guided Breathing platform delivers significant results without side effects, yet is easy to use, natural and non-invasive.
  
  
• Cleared Technology, Clinical and Regulatory Hurdles
  75,000 RESPeRATE devices are now in use in markets around the world. Over-the-counter regulatory clearance achieved in the US, Europe and most major markets. Supported by clinical data from 7 studies performed in three continents and published in peer reviewed medical journals.
  
  
• Proven Market Demand and High Growth
  Near triple-digit growth from direct-to-consumer sales has established a meaningful footprint. Retail drugstore distribution will increase accessibility, awareness, credibility and growth.
  
  
• Significant Therapeutic Brand in the Making
  RESPeRATE’s website has already become one of the most trafficked hypertension product destinations. Massive print advertising campaigns further enable brand growth.
  
  
• Experienced Management Team, Scalable Infrastructure in Place
  Led by its founding trio (Chairman, CEO & CSO), the Company attracted some of the most experienced executives in the field. The team has put in place an impressive infrastructure for developing and commercializing personal therapeutic devices including highly advanced direct marketing capabilities for both consumers and professionals.
  
  
• Strong IP Platform
  InterCure has carefully pursued a comprehensive program of intellectual property protection and has received multiple US and international method and device patents. It has received broad patents on a fundamental “method for manipulating biological rhythmic patterns,” such as respiration and blood vessel movement.